SynAct Pharma AB - ESG Rating & Company Profile powered by AI
This analysis of SynAct Pharma AB incorporates data points from across the internet as well as from available filings by SynAct Pharma AB. This Disclosure score covers 17 United Nations SDGs including: 'Clean Water & Sanitation', 'Sustainable Cities & Communities' and 'Partnerships for the Goals'. Alternative corporations in the scoring industry group for SynAct Pharma AB are shownin the table.
SynAct Pharma AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.4; made up of an environmental score of 8.0, social score of 6.4 and governance score of 4.8.
6.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 389 | WuXi Biologics (Cayman) Inc | 6.6 | High |
| 401 | Oxford Cannabinoid Technologies Holdings PLC | 6.5 | High |
| 402 | SynAct Pharma AB | 6.4 | High |
| 402 | Capricor Therapeutics Inc | 6.4 | High |
| 402 | Alembic Pharmaceuticals Ltd | 6.4 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does SynAct Pharma AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes SynAct Pharma AB disclose current and historical energy intensity?
Sign up for free to unlockDoes SynAct Pharma AB report the average age of the workforce?
Sign up for free to unlockDoes SynAct Pharma AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes SynAct Pharma AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes SynAct Pharma AB disclose cybersecurity risks?
Sign up for free to unlockDoes SynAct Pharma AB offer flexible work?
Sign up for free to unlockDoes SynAct Pharma AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes SynAct Pharma AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes SynAct Pharma AB conduct supply chain audits?
Sign up for free to unlockDoes SynAct Pharma AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes SynAct Pharma AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes SynAct Pharma AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes SynAct Pharma AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes SynAct Pharma AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes SynAct Pharma AB disclose water use targets?
Sign up for free to unlockDoes SynAct Pharma AB have careers partnerships with academic institutions?
Sign up for free to unlockDid SynAct Pharma AB have a product recall in the last two years?
Sign up for free to unlockDoes SynAct Pharma AB disclose incidents of discrimination?
Sign up for free to unlockDoes SynAct Pharma AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas SynAct Pharma AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes SynAct Pharma AB disclose parental leave metrics?
Sign up for free to unlockDoes SynAct Pharma AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes SynAct Pharma AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes SynAct Pharma AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes SynAct Pharma AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes SynAct Pharma AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes SynAct Pharma AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs SynAct Pharma AB involved in embryonic stem cell research?
Sign up for free to unlockDoes SynAct Pharma AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes SynAct Pharma AB disclose its waste policy?
Sign up for free to unlockDoes SynAct Pharma AB report according to TCFD requirements?
Sign up for free to unlockDoes SynAct Pharma AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes SynAct Pharma AB disclose energy use targets?
Sign up for free to unlockDoes SynAct Pharma AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes SynAct Pharma AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for SynAct Pharma AB
These potential risks are based on the size, segment and geographies of the company.
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.